Ipamorelin is a synthetic pentapeptide that functions as a growth hormone secretagogue, specifically targeting the ghrelin receptor to stimulate the pituitary gland's release of growth hormone (GH). Unlike some other GH secretagogues, Ipamorelin exhibits a high degree of selectivity, minimizing the activation of cortisol and prolactin, which can lead to fewer side effects. Clinically, Ipamorelin is often utilized for its potential to enhance muscle hypertrophy, improve recovery from injuries, and support lipolysis, making it beneficial in both therapeutic and performance enhancement contexts. Additionally, it is explored in anti-aging medicine due to its ability to promote collagen synthesis, enhance skin elasticity, and improve overall vitality.

Tesamorelin, also known as growth hormone-releasing factor (GRF) or TH9507, is a synthetic analog of growth hormone-releasing hormone (GHRH) that is used to stimulate the release of growth hormone (GH) from the pituitary gland. It is primarily used to reduce visceral fat in HIV-infected patients with lipodystrophy, a condition characterized by abnormal fat distribution. Tesamorelin works by increasing GH levels, which in turn promotes fat loss, improves body composition, and enhances overall metabolic health. Its targeted action on GH release and effectiveness in reducing visceral fat make Tesamorelin a valuable therapeutic agent in both clinical and metabolic health settings.

5-amino-1MQ is a small molecule that inhibits the enzyme nicotinamide N-methyltransferase (NNMT), which is crucial for metabolism and energy production, primarily in fat tissue. By blocking NNMT, 5-amino-1MQ increases levels of nicotinamide adenine dinucleotide (NAD+), enhancing metabolic rate and activating the "longevity gene" SIRT1. SIRT1 helps reduce risks of diabetes, obesity, metabolic syndrome, cardiovascular diseases, and more.